Skip To Main Content
Gladis Bortoletto on Muck Rack

Gladis Bortoletto

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gladis

Contact Gladis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo)

|
By Francesco Saraceni, Emanuele Angelucci, Mario Arpinati, Andrea Bacigalupo, Giorgia Battipaglia, Fabio Benedetti, Alessandra Biffi, Carlo Borghero, Stefania Bramanti, Fabiana Cacace Verified, Irene Cavattoni, Patrizia Chiusolo, Fabio Ciceri, Carmen Di Grazia, Nicola Di Renzo, Franca Fagioli, Marta Lisa Battista, Francesca Patriarca, Valentina Giudice, Anna Grassi, Giorgio La Nasa, Lucia Brunello, Salvatore Leotta, Jacopo Mariotti, Stefano Pozzi, Fabrizio Pane, Matteo Parma, Domenico Pastore, Alessandra Picardi, Simona Piemontese, Arcangelo Prete, Alessandro Rambaldi, Daniele Avenoso, Francesco Saglio, Giorgia Saporiti, Bianca Serio, Simona Sica, Cristina Skert, Francesco Paolo Tambaro, Vincenzo Federico, Alessandro Isidori, Michele Malagola, Luca Castagna, Francesca Bonifazi, Massimo Martino, Gladis Bortoletto, Mariangela Pedata, Martina Chiarucci, Angela Cuoghi, Ilaria Foggetti, Andrea Gilioli, Annalisa Imovilli, Anna Paola Iori, Eugenia Piras, Martina Salvatori, Elisabetta Terruzzi, Manuela Tumino, Francesco Zallio, Eliana Degrandi
| Nature Verified
To the Editor: Acute myeloid leukemia (AML) relapse remains the leading cause of treatment failure in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although considerable advancements have improved post-transplant outcomes, managing high-risk AML patients or those experiencing overt relapse remains challenging due to the absence of uniform consensus guidelines. Therefore, preventive and therapeutic strategies vary widely across transplant centers.
Open in Who Shared Issue with article?
See all 1 articles